Fuliang Chu

The University of Texas MD Anderson Cancer Center

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma”.

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma

Blood Advances(2022)10.1182/bloodadvances.2021006240

N/A

1.4DataRank · unranked

47 citations

Collin K. Chin, Jason R. Westin, Nathan Fowler, Felipe Samaniego, Xiaoyun Cheng +12 more

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007515

N/A

0.434DataRank · unranked

17 citations

Jingjing Cao, Jingwei Liu, Haopeng Yang, Timothy J. Davis, Shao-Qing Kuang +11 more